


I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on January 4, 2005.

Donald S. Prater
Name (Print)


Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HELLBERG et al.) Examiner: WALLER, Robin Regina
)
Application No.: 10/723,208) Group Art Unit: 1626
)
Filed: November 26, 2003) Confirmation No.: 8524
)
Docket No.: 2162 (3010-009-01)) Customer No.: 33432
)

For: NOVEL ARYLAMINOPROPANE ANALOGUES AND THEIR USE FOR THE TREATMENT OF
GLAUCOMA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 4, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted after expiration of the three-month period following filing of the above-captioned application, but before any Final Office Action or Notice of Allowance. No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The above information is presented so that the Patent and Trademark Office can, in the first

Information Disclosure Statement
U.S. Patent Application No. 10/723,208


instance, determine any materiality thereof to the claimed invention. *See* 37 C.F.R. §§1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and the applicants determine that the cited documents do not constitute "prior art" under United States law, the applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925 and please consider this a petition.

Respectfully submitted,


Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 2162 (3010-009-01)
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO-1449, w/1 Document

Page 1 of 1

FORM PTO-1449 (REV 7-80)	Atty. Docket No. 2162 (3010-009-01)	Application No. 10/723,208
INFORMATION DISCLOSURE STATEMENT	APPLICANT: Hellberg et al.	Filing Date: November 26, 2003 Group Art Unit: 1626

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Shulgin et al., "A chemical love story," Transform Press, Berkeley, CA (1991), #86, reprinted online at www.erowid.org/library/books_online/pihkal/pihkal086

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.